Ticiana A Leal

LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

A. Tafreshi, J. Riess, M. Pietanza, 2020 .

Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes.

S. Ramalingam, S. Dahlberg, Ticiana A Leal, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non–small cell lung cancer

G. Otterson, G. Blumenschein, L. Villaruz, 2023, Cancer.

Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms.

L. Fernandez-Cuesta, M. Foll, A. Sexton-Oates, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.

J. Bradley, S. Ramalingam, K. Higgins, 2023, Cancer.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

S. Ou, J. Christensen, Melissa L. Johnson, 2020, European Journal of Cancer.

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy

M. Socinski, Ticiana A Leal, T. Leal, 2023, Expert review of anticancer therapy.

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.

C. Blakely, S. Gadgeel, D. Waterhouse, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advancing immunotherapy in small cell lung cancer

J. Carlisle, Ticiana A Leal, T. Leal, 2023, Cancer.

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.

J. Milanowski, J. Aerts, R. Ramlau, 2023, Journal of Clinical Oncology.

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

R. Greil, J. Milanowski, J. Aerts, 2023, The Lancet. Oncology.